Oncology for the Inquisitive Mind

As we "EMBARK" on our next Prostate Cancer adventure via the "SOLAR" system to "SATURN," Michael and Josh explore the idea of biochemical recurrence in prostate cancer and the role of radiotherapy in…

Marie Curie's life work laid the foundations for theranostics. This week, we talk about Lutetium, a rare earth metal, and its role in Prostate Cancer. Lutetium-177 PSMA therapy is a radiation therapy…

Prostate Cancer has a multitude of presentations, but when metastatic, it usually spreads directly to the lymph nodes or the bones. This episode focuses on the contentious definition of "M0 Castrate …

This week, we interview Dr. Cristofanilli, a globally recognised expert in inflammatory breast cancer research and precision medicine. With decades of clinical experience and groundbreaking contribut…

Today, we discuss the role of triplet therapy (ie, chemotherapy and androgen receptor signalling inhibitor and ADT) in high-volume metastatic hormone-sensitive prostate cancer and whether darolutamid…

The rise and rise of Androgen Receptor Pathway (or Signalling) Inhibitors has changed the world of metastatic prostate cancer forever. What was once a cancer with a finite number of treatment options…

Our final breast cancer episode is here! Today, we are talking about the role of Gene Expression Assays in early hormone receptor-positive breast cancer management. The specific questions we asked in…

This week, we prematurely dive into prostate cancer (one breast episode remaining - whoops!), where we explore the early pivotal trials, including the role of abiraterone in metastatic hormone-sensit…

As our breast cancer journey comes close to finishing, it was always the destiny of your cohost's on Oncology for the Inquisitive Mind to talk about HER2-positive breast cancer. This week, we target …

Metastatic Triple Negative Breast Cancer is one of the most challenging breast cancer subtypes to treat. Recurrence rates can be as high as 40%. This episode covers the role of immunotherapy and anti…

It's been an "Olympic" ride to get here, and this is our penultimate breast cancer episode! Today, we talk about the BRCA mutations and how they impact both breast cancer and outcomes using targeted …

Metastatic Hormone Receptor-Positive Breast Cancer truly represents the frontier of Medical Oncology, with life expectancy creeping up to and beyond five years. This week, we discuss Monaleesa-2 (Rib…

Early Triple Negative Breast Cancer remains an aggressive variant of all breast cancers, affecting those under 40 more and has a higher propensity for being in those with BRCA1/2 mutations. It repres…

Our second SABCS (San Antonio Breast Cancer Symposium) episode covers everything (else) you need to know from 2024.

In this episode, we dive into the role of trastuzumab deruxtecan in HR +ve, HER2 lo…

Welcome back to Oncology for the Inquisitive Mind, where we head back to late 2024 and cover some pivotal trials and ideas from the San Antonio Breast Cancer Conference 2024.

This episode broadly cove…

Before immunotherapy, targeted chemotherapy (ADCs) and precision oncology, there was endocrine therapy, the forefather (or mother) of effective treatment to reduce breast cancer recurrence as well as…

HER2 Breast Cancer is complicated, and this week, we explore those with residual disease post neoadjuvant therapy (KATHERINE) and the idea of de-escalation in a subpopulation of HER2-positive breast …

Human epidermal growth factor receptor 2 (HER2) is overexpressed in multiple cancers, including breast, gastric, colorectal, and epithelial ovarian cancers. However, this receptor's complexity doesn'…

Early Breast Cancer had one of its defining moments in the 1990s, when five years of adjuvant tamoxifen reduced the recurrence risk of invasive breast cancer by 49%! These days, those types of improv…

Breast Cancer is complex, as are the treatment options that clinicians and patients must traverse. Stage III breast cancer has up to a 57% chance of recurring up to 20 years after diagnosis. Josh and…